{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T17:33:43Z","timestamp":1787592823791,"version":"build-2736575974"},"reference-count":5,"publisher":"SAGE Publications","issue":"7-8","license":[{"start":{"date-parts":[[2002,7,1]],"date-time":"2002-07-01T00:00:00Z","timestamp":1025481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2002,7]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To report the occurrence of a novel group of adverse effects associated with initiation and rechallenge of orlistat.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CASE SUMMARY:<\/jats:title>\n                    <jats:p>A 42-year-old white woman developed symptoms of constipation, polyuria, polydipsia, and increased lower-leg edema after 2 weeks of treatment with orlistat 120 mg 3 \u00d7 daily. The drug was discontinued for 4 days and the symptoms resolved. On reinstitution of the orlistat treatment, the symptoms reappeared within 2 days. Thereafter, the medication was permanently discontinued.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DISCUSSION:<\/jats:title>\n                    <jats:p>Common gastrointestinal adverse reactions associated with orlistat use include fecal urgency and abdominal pain and discomfort. Pedal edema has also been reported to occur, although less frequently. No reports were discovered documenting the occurrence of constipation, polydipsia, and polyuria associated with the use of orlistat. Despite careful consideration of other possible causes of these symptoms, the temporal association between initiation, discontinuation, and rechallenge of orlistat and the patient's symptoms suggest a medication-related adverse event. Based on the Naranjo probability scale, the likelihood that orlistat was the cause of this cluster of adverse effects is possible.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>It is important for the healthcare provider to be aware of these adverse effects to promptly evaluate and differentiate between possible causes of similar reactions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.1a452","type":"journal-article","created":{"date-parts":[[2003,6,4]],"date-time":"2003-06-04T16:21:48Z","timestamp":1054743708000},"page":"1168-1170","source":"Crossref","is-referenced-by-count":6,"title":["Constipation, Polyuria, Polydipsia, and Edema Associated with Orlistat"],"prefix":"10.1177","volume":"36","author":[{"given":"Kathleen A","family":"Packard","sequence":"first","affiliation":[{"name":"Kathleen A Packard PharmD, Clinical Research Fellow, Creighton Cardiac Center, Omaha, NE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard L","family":"Wurdeman","sequence":"additional","affiliation":[{"name":"Richard L Wurdeman PharmD, Associate Professor, College of Pharmacy, Creighton University School of Pharmacy and Allied Health, Omaha"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio P","family":"Reyes","sequence":"additional","affiliation":[{"name":"Antonio P Reyes MD, Assistant Professor of Internal Medicine, Division of Cardiology, Creighton University School of Medicine, Omaha"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2002,7,1]]},"reference":[{"key":"bibr1-aph.1A452","volume-title":"Xenical (orlistat)","year":"1999"},{"key":"bibr2-aph.1A452","doi-asserted-by":"publisher","DOI":"10.1111\/j.0954-6820.1966.tb19403.x"},{"key":"bibr3-aph.1A452","volume-title":"Drug evaluations subscription","author":"American Medical Association Department of Drugs","year":"1983"},{"key":"bibr4-aph.1A452","doi-asserted-by":"publisher","DOI":"10.1161\/hc4001.096152"},{"key":"bibr5-aph.1A452","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1A452","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1A452","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:05:53Z","timestamp":1777374353000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1A452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,7]]},"references-count":5,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2002,7]]}},"alternative-id":["10.1345\/aph.1A452"],"URL":"https:\/\/doi.org\/10.1345\/aph.1a452","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,7]]}}}